E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Low-grade inflammation in obesity |
Laaggradige inflammatie in obesitas |
|
E.1.1.1 | Medical condition in easily understood language |
Chronic inflammation in obesity |
Chronische onsteking in obesitas |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10029883 |
E.1.2 | Term | Obesity |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 24.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10033307 |
E.1.2 | Term | Overweight |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To study the causal role of inflammation in affecting food-related effort-based decision making in brain and behaviour in obese participants by employing a placebo-controlled intervention design with the anti-inflammatory agent colchicine.
|
Het onderzoeken van de causale effect van inflammatie op het voeding-gerelateerd keuzegedrag in het brein en gedrag in mensen met obesitas, door het uitvoeren van een placebo-gecontroleerd ontstekingsremmende interventie met de ontstekingsremmer colchicine. |
|
E.2.2 | Secondary objectives of the trial |
To study whether the primary objective translate to more ecologically valid measures/settings. |
Het onderzoeken hoe de primaire doelstelling zich vertaalt in meer ecologisch valide methoden/settings. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
General inclusion criteria: • BMI ≥ 30 kg/m2 • Female sex • Age: 18-59 years • Right-handed • Low-grade inflammation, as defined by C-reactive protein (hsCRP) between 3.0 and 10.0 mg/L for BMI between 30-31 kg/m2, and hsCRP between 3.0 and 22.1 mg/L for BMI > 31 kg/m2. In case of a hsCRP level above these thresholds, the measurement is repeated after at least 4 weeks (as part of the FLAIR-o study, NL77503.091.21). For this second measurement the thresholds for inclusion are: hsCRP 3.0-19.7 for BMI between 30-31 kg/m2 and hsCRP 3.0-27.8 for BMI > 31 kg/m2.
|
Algemene inclusiecriteria: • BMI ≥ 30 kg/m2 • Geslacht: vrouw • Leeftijd: 18-59 jaar • Rechtshandig • Laaggradige inflammatie, aangetoond door C-reactive protein (hsCRP) tussen de 3.0 en 10.0 mg/L bij BMI tussen de 30-31 kg/m2, en hsCRP tussen de 3.0 en 22.1 mg/L bij BMI > 31 kg/m2 In het geval van een hsCRP waarde boven deze waarden wordt de meting na minimaal 4 weken herhaald (als onderdeel van de FLAIR-o studie, as part of the FLAIR-o study, NL77503.091.21). Bij een tweede meting gelden dan de volgende afkapwaarden als inclusie: hsCRP 3.0-19.7 mg/L voor een BMI tussen de 30-31 kg/m2 en hsCRP 3.0-27.8 mg/L voor een BMI > 31 kg/m2.
|
|
E.4 | Principal exclusion criteria |
• Diagnosed with Diabetes Mellitus type I or II • Having been vaccinated in the 4 weeks preceding the first test session • Gained or lost >5 kg of body weight over the last 6 months • Followed an energy restricting diet during the last 2 months • Habitual smoking, i.e. one or more cigarettes per day • Current or history of alcohol and/or drugs abuse (i.e. >14 units per week) • Pregnant, lactating or wishing to become pregnant in the period between the screening and until 3 months after the last study visit (self-reported) • (History of) clinically significant psychiatric or neurological disorder • (History of) clinically significant metabolic, cardiovascular, renal, endocrinological, autoimmune or chronic inflammatory disease • General medical conditions, such as sensorimotor handicaps, deafness, blindness or colorblindness, as judged by the investigator • Regular use of anti-inflammatory, anti-diabetic, anti-histamine and psychoactive medication • Regular use of CYP3A4 inhibitors, P-glycoprotein inhibitors, statins, fibrates, ciclosporin, and digoxin, as a contraindication for colchicine • Renal impairment as evidenced by serum creatinine >150 µmol/l or eGFR <50mL/min/1.73m2 • Have moderate to severe hepatic disease • Contraindications for fMRI |
• Gediagnosticeerd met Diabetes Mellitus type I of II • Gevaccineerd zijn in de 4 weken voor de eerste test sessie • >5 kg aangekomen of afgevallen in de afgelopen 6 maanden • Een energiebeperkend dieet hebben gevolgd in de afgelopen 2 maanden • Roken (1 of meer sigaretten per dag) • Huidig of vroeger alcohol- of drugsmisbruik (meer dan 14 eenheden per week) • Zwanger, borstvoeding geven of de wens hebben om zwanger te worden in periode tussen de screening en tot 3maanden na de laatste studie-afspraak (zelf gerapporteerd) • (Vroegere) klinisch significante psychiatrische stoornis of neurologische aandoening • (Vroegere) klinisch significante metabole, cardiovasculaire, endocrinologische, autoimmuun, nier- of chronische ontstekingsziekte/aandoening • Algemene medische conditie, zoals sensorimotorische handicaps, doofheid, blindheid, kleurenblindheid, zoalsbeoordeeld door de onderzoeker • Regelmatig gebruik van ontstekingsremmende, anti-diabetes, anti-histamine en psychoactieve medicatie • Regelmatig gebruik van CYP3A4 remmers, P-glycoprotein remmers, statines, fibraten, ciclosporine, and digoxine • Nierfalen, aangetoond door serum creatinine >150 µmol/l of eGFR <50mL/min/1.73m2 • Matig tot ernstige leverziekte • Contra-indicaties voor MRI |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The main outcomes are brain activity and behavioural weightings of effort and reward valuation, measured by functional MRI and by a behavioural effort-based decision-making task. |
De belangrijkste uitkomstmaten zijn hersenactiviteit en gedragsmatige wegingen van inspanning en beloning, gemeten door functionele MRI en door een taak waarin inspanningsgerelateerd keuzegedrag wordt gemeten.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At baseline (as part of a larger observatory study, the FLAIR-o) and after the trial period. |
Op baseline (deel van een grotere observationele studie, de FLAIR-o) en na de trial periode. |
|
E.5.2 | Secondary end point(s) |
Secondary outcomes are effort- and reward-related food intake in the lab, anhedonia, reward anticipation, and active behaviour in daily life, measured by Experience Sampling Method and qualitative interviews. |
Secondaire uitkomstmaten zijn inspanning- en beloning-gerelateerde voedselinname in het lab, anhedonia, anticipatie van beloning, en actief gedrag in het dagelijks leven, gemeten door de Experience Sampling Method en kwalitatieve interviews. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At baseline (as part of a larger observational study, the FLAIR-o study, NL77503.091.21) and after the intervention period. |
Op baseline (deel van een grotere observationele studie, de FLAIR-o studie, NL77503.091.21) en na de interventieperiode. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |